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Summary
Background China is increasingly facing the challenge of control of the growing burden of non-communicable 
diseases. We assessed the epidemiology of Alzheimer’s disease and other forms of dementia in China between 1990, 
and 2010, to improve estimates of the burden of disease, analyse time trends, and inform health policy decisions 
relevant to China’s rapidly ageing population.
Methods In our systematic review we searched for reports of Alzheimer’s disease or dementia in China, published in 
Chinese and English between 1990 and 2010. We searched China National Knowledge Infrastructure, Wanfang, and 
PubMed databases. Two investigators independently assessed case deﬁ nitions of Alzheimer’s disease and dementia: 
we excluded studies that did not use internationally accepted case deﬁ nitions. We also excluded reviews and 
viewpoints, studies with no numerical estimates, and studies not done in mainland China. We used Poisson 
regression and UN demographic data to estimate the prevalence (in nine age groups), incidence, and standardised 
mortality ratio of dementia and its subtypes in China in 1990, 2000, and 2010.
Findings Our search returned 12 642 reports, of which 89 met the inclusion criteria (75 assessed prevalence, 
13 incidence, and nine mortality). In total, the included studies had 340 247 participants, in which 6357 cases of 
Alzheimer’s disease were recorded. 254 367 people were assessed for other forms of dementia, of whom 3543 had 
vascular dementia, frontotemporal dementia, or Lewy body dementia. In 1990 the prevalence of all forms of dementia 
was 1·8% (95% CI 0·0–44·4) at 65–69 years, and 42·1% (0·0–88·9) at age 95–99 years. In 2010 prevalence was 2·6% 
(0·0–28·2) at age 65–69 years and 60·5% (39·7–81·3) at age 95–99 years. The number of people with dementia in 
China was 3·68 million (95% CI 2·22–5·14) in 1990, 5·62 million (4·42–6·82) in 2000, and 9·19 million (5·92–12·48) 
in 2010. In the same period, the number of people with Alzheimer’s disease was 1·93 million (1·15–2·71) in 1990, 
3·71 million (2·84–4·58) people in 2000, and 5·69 million (3·85–7·53) in 2010. The incidence of dementia was 
9·87 cases per 1000 person-years, that of Alzheimer’s disease was 6·25 cases per 1000 person-years, that of vascular 
dementia was 2·42 cases per 1000 person-years, and that of other rare forms of dementia was 0·46 cases per 
1000 person-years. We retrieved mortality data for 1032 people with dementia and 20 157 healthy controls, who were 
followed up for 3–7 years. The median standardised mortality ratio was 1·94:1 (IQR 1·74–2·45).
Interpretation Our analysis suggests that previous estimates of dementia burden, based on smaller datasets, might 
have underestimated the burden of dementia in China. The burden of dementia seems to be increasing faster than is 
generally assumed by the international health community. Rapid and eﬀ ective government responses are needed to 
tackle dementia in low-income and middle-income countries.
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Introduction
Chronic non-communicable diseases have become the 
leading cause of morbidity and mortality in low-income 
and middle-income countries.1 Over the next decade, 
the burden of non-communicable diseases will grow 
rapidly, driven mainly by increased life expectancy in 
large low-income and middle-income countries such as 
China, India, Brazil, and South Africa.2–6 Unless eﬀ ec-
tive means to prevent and control non-communicable 
diseases are implemented, the economic development 
of these countries will be hindered.7 Of the many non-
communicable diseases that need attention, dementia 
is predicted to have the greatest economic and social 
eﬀ ect. The World Alzheimer Report 2010 8 estimated that 
ageing of the global population will make the economic 
eﬀ ect of dementia greater than that of cancer, heart 
disease, and stroke combined. In China, the problem of 
dementia might become exacerbated by the one-child 
policy and large internal migration, with fewer adults of 
working age available to provide continuing care to 
the millions of people with dementia, particularly in 
rural regions.9,10
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Population surveillance data are crucial for the 
development of eﬀ ective policies and programmes for 
prevention and management of dementia, but such data 
are inadequate in most low-income and middle-income 
countries.11,12 For this reason, the ﬁ rst estimates of the 
worldwide burden of dementia have been based on a 
combination of a few reports and expert opinion.13,14 
Alzheimer’s Disease International developed the ﬁ rst 
data-driven estimate in 2009.15 Their report had reason-
able coverage for only 11 of 21 regions worldwide, it was 
restricted to patients aged 60 years or older, and the 
estimate for China was low compared with other low-
income and middle-income regions.15,16 Estimation of the 
burden in China relied on a review of 25 studies done 
between 1980, and 2004, by Chinese investigators.16 
Alzheimer’s Disease International complemented these 
sources with a search of other publicly available databases 
for more recent studies, but acknowledged that their 
inability to do a fully systematic review of Chinese work 
might be a substantial shortcoming, making their esti-
mates for east Asia provisional at best.15 The 2012 WHO 
report17 on dementia adopted the estimates of Alzheimer’s 
Disease International, but acknowledged their limitations 
and called for further epidemiological studies in low-
income and middle-income countries.
China’s academic databases are a valuable and largely 
unexplored resource for understanding the epidemiology 
of dementia and many other non-communicable dis-
eases.18–21 We did a systematic review of epidemiological 
studies of dementia and its subtypes—particularly 
Alzheimer’s disease and vascular demen tia—in both 
Chinese and English. We estimated the prevalence, 
incidence, and mortality associated with Alzheimer’s 
disease, vascular dementia, and other forms of dementia 
in China, assessing size and time trends between 
1990 and 2010. We also investigated the diﬀ erences in 
prevalence by age and sex and between rural and urban 
regions, to inform policy and priority setting.
Methods
Search strategy and exclusion criteria
We searched China National Knowledge Infrastructure, 
Wanfang, and PubMed. Searches were done in parallel 
by WW (1) and JJW. The search was limited to studies 
published between 1990, and 2010. The appendix shows 
the search terms. We excluded duplicates within and 
between the databases, studies with no numerical 
estimates, studies of Chinese populations done outside 
of mainland China, reviews, and viewpoints (appendix). 
We excluded studies of animals, studies with no 
clear denominator or inappropriate standardised rates, 
studies that assessed dementia only, men only, military 
personnel only, or were set in nursing homes, and 
studies that did not have adequate controls. We also 
excluded studies that did not adopt internationally 
recognised deﬁ nitions of Alzheimer’s disease and other 
dementia (Diagnostic and Statistical Manual of Mental 
Disorders or International Classiﬁ cation of Diseases 
criteria for dementia, National Institute of Neurological 
and Communicative Disorders and Stroke and the 
Alzheimer’s Disease and Related Disorders Association 
criteria for Alzheimer’s disease, and National Institute 
of Neurological Disorders and Stroke and Association 
Internationale pour la Recherché et l’Enseignement en 
Neurosciences criteria for vascular dementia).22–26
Procedures and statistical analyses
Consistent methods and criteria for each study are crucial 
to the accuracy and precision of our estimates.27 Two 
researchers with expertise in psychiatry, dementia, and 
cognitive ageing (TCR and IJD) independently reviewed 
all eligible studies to assess the quality of the case 
deﬁ nitions used. They used the following ratings: 
3=reported Diagnostic and Statistical Manual of Mental 
Disorders or International Classiﬁ cation of Diseases 
criteria or a similarly acceptable standard; 2=other criteria, 
but less widely accepted; 1=only basic screening for 
dementia (eg, Mini Mental State Examination); 
0=insuﬃ  cient information or no report of dementia 
criteria. We estimated age-speciﬁ c prevalences of demen-
tia in China by Poisson regression (appendix). Prevalence 
for each 5-year age group—estimated for 1990, 2000, and 
2010—was multiplied by the corresponding 5-year 
population subgroups in China, available from the UN’s 
Population Division,28 to estimate the total number of 
people with dementia, Alzheimer’s disease, vascular 
For the China National 
Knowledge Infrastructure see 
http://www.global.cnki.net
For Wanfang see http://www.
wanfangdata.com
See Online for appendix
Figure 1: Study selection
Four studies provided information on both incidence and prevalence, three on both incidence and mortality, and 
one on both prevalence and mortality. *Internet searches and monographs. †Did not provide original, numerical 
estimates of prevalence, incidence, or mortality. 
12 642 reports identified through
database search
7 records identified from 
other sources*
8477 abstracts screened 8302 excluded†
175 full-text articles assessed 
for eligibility
13 provided incidence data 9 provided mortality data75 provided prevalence data
89 studies included
86 excluded
1 non-human study
15 no clear denominator
2 incorrect standardised rates
18 assessed dementia only
3 assessed men or military 
personnel only
3 nursing home studies
18 duplicate publications
12 inadequate case definitions
14 no adequate controls for 
computing standardised 
mortality
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dementia, and other dementia in those three years. We 
then extracted information on age-speciﬁ c prevalence by 
sex and rural versus urban population when possible. We 
made a database containing: mean age for each age group 
reported in the study; number of participants in each age 
group; and proportion of participants diagnosed with 
Alzheimer’s disease, other forms of dementia (if available), 
and any form of dementia.
We estimated incidence from prospective studies 
that enrolled healthy cohorts and then assessed the 
cohorts for development of Alzheimer’s disease, 
vascular dementia, other types of dementia, and all 
dementia. We recorded the number of new cases in 
people aged 60 years or older at the beginning of the 
study, to make the estimates com parable. We then 
added the number of new cases and person-years across 
studies and expressed the incidence as the number of 
new cases per 1000 person-years. We also estimated the 
increase in mortality of patients with dementia com-
pared with healthy controls. We adjusted mortality rate 
ratios in the studies for the baseline diﬀ erence in 
expected mortality and estimated standardised mortality 
ratio. The appendix provides further details of modelling 
and statistical analyses.
 Number 
of studies 
(%; N=75)
Sample size (n)
<500 3 (4%)
500–1000 2 (3%)
1001–2000 17 (23%)
2001–5000 34 (45%)
>5000 19 (25%)
Year published
1990–94 5 (7%)
1995–99 17 (23%)
2000–04 29 (39%)
2005–10 24 (32%)
Setting
Urban 24 (32%)
Rural 14 (19%)
Both 37 (49%)
Main case deﬁ nition*
DSM 71 (95%)
DSM-III 10 (13%)
DSM-III-R 28 (37%)
DSM-IV 23 (31%)
DSM-IV-TR 10 (13%)
NINCDS-ADRDA 43 (57%)
NINDS-AIREN 22 (29%)
ICD 22 (29%)
ICD-9 2 (3%)
ICD-10 18 (24%)
CCMD 13 (17%)
CCMD-II 1 (1%)
CCMD-II-R 6 (8%)
CCMD-III 1 (1%)
CCMD-III-R 4 (5%)
Additional diagnostic tests used to establish case deﬁ nition*
Mini-Mental State Examination 74 (99%)
Hachinski Ischemic Score 63 (84%)
Activities of daily living 46 (61%)
Health status or disease history 44 (59%)
Physical examination (height, weight, blood pressure, 
and other)
34 (45%)
Neurological assessment 31 (41%)
(Continues in next column)
 Number 
of studies 
(%; N=75)
(Continued from previous column)
Fuld Object Memory Evaluation 30 (40%)
Pfeiﬀ er Function Activity questionnaire 28 (37%)
Wechsler Adult Intelligence Scale digit span 26 (35%)
Basic demographic information 26 (35%)
Wechsler Adult Intelligence Scale block design 23 (31%)
Rapid Vocabulary Retrieve 21 (28%)
Hamilton Depression Rating Scale 20 (27%)
CT or MRI 17 (23%)
Hastgawa Dementia Scale 16 (21%)
Clinical Dementia Rating Scale 16 (21%)
Verbal Fluency Test 10 (13%)
Family history 10 (13%)
Center for Epidemiologic Studies Depression Scale 10 (13%)
Key informant survey (for those who are alive but have 
severe dementia, are deaf, have symptoms, or whose 
health status prevents interview)
10 (13%)
Crichton Royal Behavioural Scale 8 (11%)
Lifestyle issues 7 (9%)
Key informant survey (for those who died) 7 (9%)
Blood tests 7 (9%)
Global Deterioration Scale 7 (9%)
Clock Drawing Test 6 (8%)
Wechsler Adult Intelligence Scale 5 (7%)
Assessor
Multidisciplinary team of psychiatrists, neurologists, and 
other medical specialties, with or without trained ﬁ eld staﬀ 
51 (68%)
Psychiatrists with trained ﬁ eld staﬀ 16 (21%)
Neurologists with trained ﬁ eld staﬀ 2 (3%)
Not speciﬁ ed 6 (8%)
We included 75 cross-sectional studies. CCMD=Chinese classiﬁ cation of mental 
disorders. ICD=International classiﬁ cation of diseases. NINDS-AIREN=National 
Institute of Neurological and Communicative Disorders and Stroke and 
Association Internationale pour la Recherche et I’Enseignement en Neurosciences. 
NINCDS-ADRDA=National Institute of Neurological and Communicative 
Disorders and Stroke and the Alzheimer’s Disease and Related Disorders 
Association. DSM=Diagnostic and Statistical Manual of Mental Disorders. *Several 
tests were typically used in each study. The tests listed here were used in at least 
ﬁ ve studies, the appendix shows a full list of tests used in each study.
Table 1: Characteristics of the cross-sectional studies
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Role of the funding source
The sponsor of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had ﬁ nal 
responsibility for the decision to submit for publication.
Results
Our initial screen returned 8490 results from 
China National Knowledge Infrastructure, 4142 from 
Wanfang, and ten from PubMed. 89 studies met all the 
inclusion criteria (ﬁ gure 1). The appendix shows a full 
list of studies included, table 1 shows details of the 
75 cross-sectional studies. The cross-sectional studies 
were mainly large, published in the past decade, and 
were led by multi disciplinary teams of specialists. They 
included patients from nearly all of the mainland 
Chinese provinces, with the exception of two sparsely 
populated provinces and three autonomous regions 
(appendix). The appendix lists all the diagnostic tests 
and criteria used in each study and we discuss diﬀ erent 
case deﬁ nitions of dementia.22–26 The appendix also 
shows interobserver agreement, available from 
32 studies (median κ 0·88, IQR 0·82–0·92).
Most studies (75 of 89; 84%) provided estimates of 
the prevalence of Alzheimer’s disease and dementia 
(ﬁ gure 2), rather than of incidence or mortality, probably 
because cross-sectional studies are much cheaper and 
easier to do than are longitudinal studies. 340 247 par-
ticipants were included in our analysis representing 
6357 cases of Alzheimer’s disease. 254 367 partici pants 
were included in our analysis of dementia, includ ing 
Figure 2: Prevalence of Alzheimer’s disease and any dementia in 75 studies
The size of each bubble is proportional to sample size. Data are presented for Alzheimer’s disease in 1990 (A), 2000 (B), and 2010 (C), and for any dementia in 1990 (D), 
2000 (E), and 2010 (F). 
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3543 cases of vascular dementia, frontotemporal demen-
tia, or Lewy body dementia. The appendix shows the 
proportion of dementias that were Alzheimer’s disease 
within each 5-year age group.
Table 2 shows the age-speciﬁ c prevalence of Alz-
heimer’s disease and dementia in 1990, 2000, and 2010. 
In 1990, the prevalence of Alzheimer’s disease ranged 
from 0·1% in people aged 55–59 years to 28·8% for those 
aged 95–99 years. The prevalence of all forms of dementia 
in 1990 ranged from 0·5% in people aged 55–59 years to 
42·1% in people aged 95–99 years. In 2010, the prevalence 
of Alzheimer’s disease was 0·2% (95% CI 0·0–72·3) in 
people aged 55–59 years and 48·2% (19·0–77·4) for those 
aged 95–99 years, with the prevalence of all forms of 
dementia ranging between 0·7% (0·0–54·5) and 60·5% 
(39·7–81·3; table 2). 
The number of people with some form of dementia in 
China was 3·68 million (95% CI 2·22–5·14) in 1990, 
5·62 million (4·42–6·82) in 2000, and 9·19 million 
(5·92–12·48) in 2010. The number of people with 
Alzheimer’s disease was 1·93 million (1·15–2·71) in 
1990, 3·71 million (2·84–4·58) people in 2000, and 5·69 
million (3·85–7·53) in 2010. Throughout this period, 
the proportion of Alzheimer’s disease in all forms of 
dementia did not change substantially (ﬁ gure 3). In 
people aged 55–59 years, roughly a third of patients 
with dementia met the criteria for Alzheimer’s disease 
compared with four ﬁ fths of patients aged 95–99 years 
(appendix). Most cases of dementia in China in all three 
periods were in people aged 70–84 years (ﬁ gure 3).
47 of the 75 prevalence studies reported the prevalence 
of dementia attributable to vascular dementia and other 
forms of dementia (eg, frontotemporal dementia, Lewy 
body dementia). The median proportion of vascular 
dementia in all forms of dementia was 24·2% 
(IQR 17·4–32·7). Rare forms of dementia (excluding 
Alz heimer’s disease and vascular dementia) constituted 
7·5% (IQR 2·7–10·7) of all dementias, which accords 
with our estimates of incidence estimates and previously 
published reports.17,22–25
Adjusted for Studies included in 
anaylsis (n; participants)
Prevalence ratio p value
Alzheimer’s disease
Women vs men Age, period of 
study, urban or 
rural dwelling
32 (123 024 participants) 2·37 (95% CI 1·90–2·96) <0·0001
Urban dwellers vs rural Age, period of 
study, sex
32 (123 024 participants) 1·34 (95% CI 0·93–1·94) 0·1150
Dementia
Women vs men Age, period of 
study, urban or 
rural dwelling 
environment
23 (79 080 participants) 1·65 (95% CI 1·51–1·81) <0·0001
Urban dwellers vs rural Age, period of 
study, sex
23 (79 080 participants) 1·54 (95% CI 0·85–2·78) 0·1510
Table 3: The eﬀ ects of sex and urban or rural environment on the prevalence of Alzheimer’s disease and 
dementia in China
1990 2000 2010
Alzheimer’s disease Dementia Alzheimer’s disease Dementia Alzheimer’s disease Dementia
55–59 years 0·0014 (0·0000–0·8378) 0·0047 (0·0000–0·6702) 0·0020 (0·0000–0·7032) 0·0055 (0·0000–0·5006) 0·0023 (0·0000–0·7227) 0·0068 (0·0000–0·5451)
60–64 years 0·0033 (0·0000–0·6410) 0·0094 (0·0000–0·5266) 0·0048 (0·0000–0·4547) 0·0109 (0·0000–0·3328) 0·0055 (0·0000–0·4982) 0·0135 (0·0000–0·3830)
65–69 years 0·0076 (0·0000–0·5304) 0·0180 (0·0000–0·4438) 0·0110 (0·0000–0·2781) 0·0209 (0·0000–0·2248) 0·0127 (0·0000–0·3612) 0·0258 (0·0000–0·2816)
70–74 years 0·0164 (0·0000–0·4946) 0·0332 (0·0000–0·4170) 0·0237 (0·0000–0·1901) 0·0387 (0·0000–0·1869) 0·0273 (0·0000–0·3178) 0·0476 (0·0000–0·2460)
75–79 years 0·0330 (0·0000–0·5040) 0·0592 (0·0000–0·4323) 0·0478 (0·0000–0·1912) 0·0690 (0·0000–0·2052) 0·0552 (0·0000–0·3391) 0·0850 (0·0000–0·2639)
80–84 years 0·0625 (0·0000–0·5337) 0·1019 (0·0000–0·4782) 0·0904 (0·0000–0·2292) 0·1187 (0·0000–0·2448) 0·1044 (0·0000–0·3862) 0·1463 (0·0000–0·3137)
85–89 years 0·1109 (0·0000–0·5785) 0·1694 (0·0000–0·5564) 0·1604 (0·0459–0·2750) 0·1974 (0·1011–0·2937) 0·1854 (0·0000–0·4500) 0·2432 (0·927–0·3937)
90–94 years 0·1847 (0·0000–0·6549) 0·2720 (0·0000–0·6840) 0·2671 (0·1596–0·3746) 0·3168 (0·2469–0·3866) 0·3086 (0·0595–0·5578) 0·3903 (0·2416–0·5389)
95–99 years 0·2884 (0·0000–0·7974) 0·4214 (0·0000–0·8892) 0·4171 (0·2070–0·6273) 0·4908 (0·3506–0·6311) 0·4819 (0·1904–0·7735) 0·6047 (0·3967–0·8128)
Data are prevalence (95% CI).
Table 2: Estimates of the age-speciﬁ c prevalence of Alzheimer’s disease and all forms of dementia in China in 1990, 2000, and 2010
Figure 3: Predicted numbers of people with any form of dementia and Alzheimer’s disease in China by year 
and age group
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We investigated whether age-speciﬁ c prevalence was 
higher in women than in men, and in rural regions than 
in urban regions (table 3). The prevalence of dementia 
controlled for age is higher for women than for men but 
did not diﬀ er signiﬁ cantly between urban residents and 
rural residents (table 3, appendix). The same patterns 
hold for Alzheimer’s disease (table 3, appendix).
We used data from 13 prospective studies to estimate 
incidence. The number of person-years of follow-up 
diﬀ ered between studies of Alzheimer’s disease, vascular 
dementia, other dementia, and all dementia (appendix). A 
mean of 30 770 people, aged 60 years or older, were 
assessed for all four diseases. They were followed up for 
an average of 71 518 person-years. Based on 32 116 people 
from these prospective studies, the incidence of dementia 
in people aged 60 years or older (90 840 person-years of 
follow-up), was 9·87 cases per 1000 person-years. The 
incidence of Alzheimer’s disease was 6·25 cases per 
1000 person-years, for vascular dementia it was 2·42 cases 
per 1000 person-years, and for rare forms of dementia 
(eg, frontotemporal dementia, Lewy body dementia) it 
was 0·46 cases per 1000 person-years (appendix). These 
incidences accord with previous reports.13,17,22,29
Nine studies provided information on mortality rate 
ratios between patients with dementia and unaﬀ ected 
people. 1032 people with dementia and 20 157 healthy 
controls were followed up for 3–7 years. Median mortality 
was 132 deaths per 1000 person-years (IQR 130–190) in 
patients with dementia and 38 deaths per 1000 person-
years in healthy controls. The median mortality rate ratio 
was 4·6 (IQR 2·42–5·71), but no adjustment was made 
for the diﬀ erence in the mean age; healthy controls were 
likely to be older and have higher expected baseline 
mortality than participants with dementia. The median 
standardised mortality ratio was 1·94 (IQR 1·74–2·45), 
which is similar to an estimate of 2·77 by Prince 
and colleagues.29
Discussion
This study is, to our knowledge, the ﬁ rst large-scale 
systematic analysis of the epidemiology of Alzheimer’s 
disease and other forms of dementia in a low-income or 
middle-income setting. It aims to address a major gap in 
policy-relevant health information and sets an example 
for further similar analyses.30 The information available 
in the Chinese scientiﬁ c literature was suﬃ  cient to 
generate reasonably precise estimates of the prevalence 
and incidence of Alzheimer’s disease and other forms of 
dementia in China over the past two decades. The 
prevalence of Alzheimer’s and dementia increased 
substantially between 1990 and 2010. The prevalences 
also diﬀ er signiﬁ cantly by sex. These ﬁ ndings have 
important policy implications because women in China 
have a considerably longer life expectancy than do men 
and constitute up to 75% of the population of people 
aged 85 years and older.28 Furthermore, migration of 
young adults from rural to urban regions within China 
will result in large numbers of elderly people, especially 
women, in rural regions living alone. Those who develop 
any form of dementia will be at an increased risk of 
becoming vulnerable and isolated, requiring community 
support and being dependent on government-supported 
programmes of care.
China had more cases of Alzheimer’s disease in 
2010 than any other country in the world.15 Our data 
suggest that the most recent Alzheimer’s Disease 
International estimates15 for China and east Asia, which 
relied on an earlier review16 of the Chinese scientiﬁ c 
literature and were adopted by WHO,17 might 
underestimate the true burden of disease in China by 
double. Our study alone suggests that global estimates of 
Alzheimer’s disease might need to be revised upwards by 
at least 5 million cases, or almost 20%. For a direct 
comparison with the World Alzheimer Report, in which all 
estimates apply only to people aged 60 years or older, the 
cases in patients younger than 60 years in our study 
should be removed, reducing this diﬀ erence slightly. 
Nevertheless, the absolute numbers of 5·69 million cases 
of Alzheimer’s disease and 9·19 million cases of any 
dementia in China in 2010 might pose the single largest 
challenge to health and social care systems in terms of 
ﬁ nding appropriate and aﬀ ordable responses. Future 
research in China should give more attention to 
quantifying the burden of disease in speciﬁ c ethnic and 
cultural groups and exploring reasons for, and con-
sidering the policy implications of, any diﬀ erences.
Although we have aimed to provide the best possible 
estimate of the prevalence of dementia in China, our 
study has some important limitations. First, although we 
selected studies of suﬃ  cient quality done in nearly all 
provinces in China, our sample is small for a country of 
1·4 billion people. Thus, the overall data on dementia in 
China are still insuﬃ  cient: many studies did not provide 
prevalence data disaggregated by sex, urban or rural 
residence, and subtype of dementia. Second, no studies 
have been done in the less developed provinces and 
autonomous regions of western China (Gansu, Qinghai, 
Inner Mongolia, Tibet, and Ningxia), although these 
regions are relatively sparsely populated compared with 
the rest of China (appendix). Methods did not vary much 
between studies; most studies were either cross-sectional 
or had a cross-sectional follow-up within a cohort study. 
All incidences and mortalities were calculated with a 
cohort study design and used person-years of follow-up, 
enabling direct comparison. All included studies were 
community-based, to avoid the many biases present in 
facility-based studies or in other studies relevant only to 
speciﬁ c population subgroups. Nevertheless, the validity 
of the data is heavily reliant on the sensitivity and 
speciﬁ city of the screening methods and diagnostic 
criteria, and standardisation of these methods is im-
portant to reduce observational bias.
Diagnoses of dementia, Alzheimer’s disease, and 
vascular dementia were based on internationally accepted 
Articles
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deﬁ nitions and were similar across studies. The large 
overlap in case deﬁ nitions between studies suggests that 
the data are generally comparable. Between 1990, and 
2010, no major revisions of the diagnostic criteria of 
Alzheimer’s disease and dementia occurred that would 
invalidate the analysis of time trends (appendix), 
although we cannot exclude the possibility that recent 
studies have used more rigorous methods and quality 
control. Awareness of the disease has increased, which 
might have increased diagnosis of milder and earlier 
cases compared with 20 years ago. The eﬀ ects of several 
other possible biases, such as publication bias, sex-
speciﬁ c diﬀ erences in survival in China, the possible 
eﬀ ect of inadequately applied multiphase designs, 
misclassiﬁ cation bias, and time lag between study and 
publication are discussed further in the appendix.31–34
Our data suggest that the prevalence of dementia in 
low-income and middle-income countries is higher than 
that previously estimated.31,35,36 Traditionally, research and 
media attention in China have often focused on diseases 
with higher case-fatality rates—eg, cardio vascular 
diseases and cancer. The general lack of awareness of 
dementia has important consequences; people do not 
seek medical help as frequently as do patients in high-
income countries, and little training is given for the 
recognition and management of dementia at all levels of 
the health service.37 These factors create a multifaceted 
burden on the individual, their family, and society, which 
has personal, emotional, ﬁ nancial, and social aspects.8 
Because of the substantial care needed by people with 
dementia, family and friends become an important 
support network, but the reliability and universality of 
family care systems in low-income and middle-income 
countries are often overestimated.37 With a growing 
middle class, this situation is likely to change as family 
structures become more like those in high-income 
countries and family support becomes less available.38,39 
However, a response purely from strained health services 
is unlikely to be suﬃ  cient, and wider societal action and 
innovative solutions will be needed.
Policy makers in China and other low-income and 
middle-income countries face several additional chal-
lenges. Mental and neurological disorders are generally 
low priorities in such countries, but our analysis shows 
that dementia prevalence in China already matches that 
of high-income countries, and will continue to accelerate. 
Adequate resources should be provided at the national, 
local, family, and individual levels to tackle this rapidly 
growing problem, including specialised care to ensure 
timely and appropriate prevention, diagnosis, and treat-
ment.40,41 Public awareness campaigns should be used to 
counteract common misconceptions about dementia—
eg, that it is not very common in the Chinese population, 
that it is a normal part of ageing, or that it is better not to 
know about it because nothing can be done to help.30 
Peoples’ cultures and beliefs should be considered when 
developing campaigns to raise awareness. Healthcare 
workers should be well trained in management of 
dementia, with the ability to assess, diagnose, treat or 
refer, and educate patients and their caregivers.42,43 
Moreover, concern is growing that governmental homes 
for the elderly have an unfair advantage over non-
governmental homes, which might hinder the develop-
ment of an elderly home industry in a free-market system 
and generate a widening gap between wealthy and poor 
elderly people in their access to care.44 A key policy 
priority should therefore be to plan for the long-term care 
of people with dementia and assess models of delivery of 
community-based care.45 Additionally, more research 
should be done to improve understanding of the diﬀ erent 
social and environmental risk factors for dementia.46–48
Contributors
KYC had the idea for the study, supervised the literature review, 
constructed the database, wrote the report, and oversaw the design, 
writing, and revision of the report. WW (1) and JJW reviewed the 
published work and wrote the report. LL and ET analysed data and 
revised the report. JC helped to construct the database and wrote the 
report. LM designed the study, interpreted data, and reviewed the report. 
TCR and IJD analysed data and wrote the report. HC, WW (2), and IR 
oversaw the study design and analysis. HC and WW (2) wrote and 
revised the report. IR wrote and revised the report.
Conﬂ icts of interest
We declare that we have no conﬂ icts of interest.
Acknowledgments
This study was supported by research grants from the Nossal Institute of 
Global Health (University of Melbourne, Australia) and the National 12th 
Five-Year Major Projects of China (grant number 2012BAI37B03). KYC 
was supported by an National Health and Medical Research Council 
Australia–China Exchange Fellowship. WW (2) was supported by the 
Importation and Development of High-Calibre Talents Project of Beijing 
Municipal Institutions. HC and IR were supported by a grant from 
Bill & Melinda Gates Foundation.
References
1 WHO. Global status report on non-communicable diseases 2010: 
description of the global burden of NCDs, their risk factors and 
determinants. Geneva: World Health Organization, 2011.
2 Mathers CD, Loncar D. Projections of global mortality and burden 
of disease from 2002 to 2030. PLoS Med 2006; 3: e442.
3 Yang G, Kong L, Zhao W, et al. Emergence of chronic 
non-communicable diseases in China. Lancet 2008; 372: 1697–705.
4 Patel V, Chatterji S, Chisholm D, et al. Chronic diseases and 
injuries in India. Lancet 2011; 377: 413–28.
5 Schmidt MI, Duncan BB, Azevedo e Silva G, et al. Chronic 
non-communicable diseases in Brazil: burden and current 
challenges. Lancet 2011; 377: 1949–61.
6 Mayosi BM, Flisher AJ, Lalloo UG, Sitas F, Tollman SM, 
Bradshaw D. The burden of non-communicable diseases in South 
Africa. Lancet 2009; 374: 934–47.
7 Abegunde DO, Mathers CD, Adam T, Ortegon M, Strong K. 
The burden and costs of chronic diseases in low-income and 
middle-income countries. Lancet 2007; 370: 1929–38.
8 ADI. World Alzheimer Report 2010. London: Alzheimer’s Disease 
International, 2010.
9 China Institute for Reform and Development. China Human 
Development Report 2007/08. Access for all: basic public services 
for 1·3 billion people. Beijing: China Translation and Publishing 
Corporation, 2008: 1–221.
10 Sousa RM, Ferri CP, Acosta D, et al. Contribution of chronic 
diseases to disability in elderly people in countries with low and 
middle incomes: a 10/66 Dementia Research Group population-
based survey. Lancet 2009; 374: 1821–30.
11 Alwan A, MacLean DR, Riley LM, et al. Monitoring and surveillance 
of chronic non-communicable diseases: progress and capacity in 
high-burden countries. Lancet 2010; 376: 1861–68.
Articles
www.thelancet.com   Vol 381   June 8, 2013 2023
30 George-Carey R, Adeloye D, Chan KY, et al. An estimate of the 
prevalence of dementia in Africa: a systematic analysis. 
J Glob Health 2012; 2: 20401.
31 Llibre Rodriguez JJ, Ferri CP, Acosta D, et al, 10/66 Dementia 
Research Group. Prevalence of dementia in Latin America, India, 
and China: a population-based cross-sectional survey. Lancet 2008; 
372: 464–74.
32 Parad’so MN, Guerchet M, Saizonou J, et al. Prevalence of dementia 
among elderly people living in Cotonou, an urban area of Benin 
(West Africa). Neuroepidemiology 2011; 36: 245–51.
33 Ineichen B. The epidemiology of dementia in Africa: a review. 
Soc Sci Med 2000; 50: 1673–77.
34 Ochayi B, Thacher TD. Risk factors for dementia in central Nigeria. 
Aging Ment Health 2006; 10: 616–20.
35 Kalaria RN, Maestre GE, Arizaga R, et al; World Federation of 
Neurology Dementia Research Group. Alzheimer’s disease and 
vascular dementia in developing countries: prevalence, 
management, and risk factors. Lancet Neurol 2008; 7: 812–26.
36 Song Y, Wang J. Overview of Chinese research on senile dementia 
in mainland China. Ageing Res Rev 2010; 9 (suppl 1): S6–12.
37 WHO. Neurological disorders: public health challenges. Geneva: 
World Health Organization, 2006.
38 Prince M, Patel V, Saxena S, et al. No health without mental health. 
Lancet 2007; 370: 859–77.
39 Chen Z, Yu J, Song Y, Chui D. Aging Beijing: challenges and 
strategies of health care for the elderly. Ageing Res Rev 2010; 
9 (suppl 1): S2–5.
40 Hipgrave D. Perspectives on the progress of China’s 
2009–2012 health system reform. J Glob Health 2011; 1: 142–47.
41 Chan KY. A health policy and systems approach to addressing the 
growing burden of noncommunicable diseases in China. 
J Glob Health 2011; 1: 28–31.
42 Allotey P, Reidpath DD, Yasin S, Chan CK, de-Graft Aikins A. 
Rethinking health-care systems: a focus on chronicity. Lancet 2011; 
377: 450–51.
43 ADI. World Alzheimer Report 2011. London: Alzheimer’s Disease 
International, 2011.
44 Zhan HJ, Liu G, Guan X, Bai HG. Recent developments in 
institutional elder care in China: changing concepts and attitudes. 
J Aging Soc Policy 2006; 18: 85–108. 
45 Xu Q, Chow JC. Exploring the community-based service delivery 
model: Elderly care in China. Int Soc Work 2011; 54: 374–87.
46 Beaglehole R, Bonita R, Horton R, et al. Priority actions for the 
non-communicable disease crisis. Lancet 2011; 377: 1438–47.
47 Russ TC, Batty GD, Hearnshaw GF, Fenton C, Starr JM. 
Geographical variation in dementia: systematic review with 
meta-analysis. Int J Epidemiol 2012; 41: 1012–32.
48 Rudan I, Lawn J, Cousens S, et al. Gaps in policy-relevant 
information on burden of disease in children: a systematic review. 
Lancet 2005; 365: 2031–40.
12 Beaglehole R, Horton R. Chronic diseases: global action must 
match global evidence. Lancet 2010; 376: 1619–21.
13 Fratiglioni L, De Ronchi D, Agüero-Torres H. Worldwide prevalence 
and incidence of dementia. Drugs Aging 1999; 15: 365–75.
14 Ferri CP, Prince M, Brayne C, et al. Global prevalence of dementia: 
a Delphi consensus study. Lancet 2005; 366: 2112–17.
15 ADI. World Alzheimer Report 2009. London: Alzheimer’s Disease 
International, 2009.
16 Dong MJ, Peng B, Lin XT, Zhao J, Zhou YR, Wang RH. 
The prevalence of dementia in the People’s Republic of China: 
a systematic analysis of 1980–2004 studies. Age Ageing 2007; 
36: 619–24.
17 WHO. Dementia: a public health priority. Geneva: World Health 
Organization, 2012.
18 Feng XL, Theodoratou E, Liu L, et al. Social, economic, political and 
health system and program determinants of child mortality 
reduction in China between 1990 and 2006: a systematic analysis. 
J Glob Health 2012; 2: 10405.
19 Rudan I, Chan KY, Zhang JS, et al, WHO/UNICEF’s Child Health 
Epidemiology Reference Group (CHERG). Causes of deaths in 
children younger than 5 years in China in 2008. Lancet 2010; 
375: 1083–89.
20 Xia J, Wright J, Adams CE. Five large Chinese biomedical 
bibliographic databases: accessibility and coverage. 
Health Info Libr J 2008; 25: 55–61.
21 Fung ICH. Chinese journals: a guide for epidemiologists. 
Emerg Themes Epidemiol 2008; 5: 20.
22 Reitz C, Brayne C, Mayeux R. Epidemiology of Alzheimer’s disease. 
Nat Rev Neurol 2011; 7: 137–52.
23 McKhann G, Drachman D, Folstein M, Katzman R, Price D, 
Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report on the 
NINCDS-ADRDA work group under the auspices of Department of 
Health and Human Services Task Force on Alzheimer’s Disease. 
Neurology 1984; 34: 939–44.
24 Savva GM, Wharton SB, Ince PG, Forster G, Matthews FE, 
Brayne C. Age, neuropathology and dementia. NEJM 2009; 
360: 2302–09.
25 Alzheimer’s Association. 2010 Alzheimer’s disease facts and 
ﬁ gures. Alzheimers Dement 2010; 6: 158–94.
26 Ballard CG, Bannister C. Criteria in the diagnosis of dementia. 
In: Burns A, O’Brien J, Ames D, eds: Dementia, 3rd edn. London: 
Hodder, 2005: 24–37.
27 Campbell H, Biloglav Z, Rudan I. Reducing bias from test 
misclassiﬁ cation in burden of disease studies: use of test to actual 
positive ratio—new test parameter. Croat Med J 2008; 48: 402–14.
28 United Nations. World Population Prospects, the 2010 Revision. 
2011. http://esa.un.org/unpd/wpp/Excel-Data/mortality.htm 
(accessed April 19, 2012).
29 Prince M, Acosta D, Ferri CP, et al. Dementia incidence and 
mortality in middle-income countries, and associations with 
indicators of cognitive reserve: a 10/66 Dementia Research Group 
population-based cohort study. Lancet 2012; 380: 50–58.
